drugset / Trial / NCT07281079
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.
Timeline
- Start
- 2025-11-12
- Primary completion
- 2027-10-31
- Completion
- 2027-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NNZ-2591 | Small molecule | — | Oral |